Diagnoplex Receives $1.4M from Investors to Support Colon Cancer Test | GenomeWeb

NEW YORK (GenomeWeb News) – Diagnoplex and Debiopharm Diagnostics, part of the Debiopharm Group, today announced that Diagnoplex has secured CHF1.3 million ($1.4 million) in financing.

Debiopharm led the round, while Neomed and Capital Romandie also participated in the financing.

Diagnoplex will use the funds to support its efforts to obtain CE marking for Colox, a non-invasive, blood-based test for the early detection of colorectal cancer. The Lausanne, Switzerland-based firm also hopes to prepare a comparative clinical trial for Colox.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In Nature this week: modern European bison analysis, phased diploid genome assembly algorithms, and more.

Actress Jennifer Lopez is working with NBC on a CRISPR-inspired television show, according to the Hollywood Reporter.

Researchers trace the origin of one human papillomavirus lineage to Neanderthals or Denisovans, Vox reports.

The BabySeq project faces lower-than-expected enrollment rates, according to ScienceInsider.